Analyst upgrades typically lead to positive short-term price movement as they reflect a positive change in the analyst's view of the company's future prospects. The upgrade from Neutral to Buy suggests a strong confidence in Nuvation Bio's potential for growth, and the $5 price target indicates a significant upside from current levels. This is likely to attract investor interest and drive up the stock price in the short term.